Rentosertib inhaled formulation
Insilico Medicine: company profile
IND in effect (China CDE) per company
Since , the date of the source that reports this phase.
Summary
Rentosertib inhaled formulation is a program from Insilico Medicine. The source describes it as small molecule (inhaled). It is being developed for idiopathic pulmonary fibrosis. Per the company, it was at IND in effect (China CDE) as of Apr 28, 2026. The AI role named in the source is molecule design. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Apr 28, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Idiopathic pulmonary fibrosis
- Therapeutic area
- Respiratory
- Modality
- Small molecule (inhaled)
- AI role
- Molecule design
- Phase in the source
- IND in effect (China CDE), as of Apr 28, 2026
- Phase source
- Confirmed
- Board column
- IND
- Trial record
- none found; China CDE IND, ChiCTR not reachable by simple fetch
AI evidence
AI source: Company
“Rentosertib (ISM001-055), the company’s first-in-class drug candidate with AI-identified novel target and AI-developed molecule structure”
Milestone timeline
-
Company release: IND in effect (China CDE)
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.